We are live on ! Find out more
COGT icon

Cogent Biosciences
COGT

69 hedge funds and large institutions have $303M invested in Cogent Biosciences in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

145% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 11

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

0% more funds holding

Funds holding: 69 → 69 (0)

17% less funds holding in top 10

Funds holding in top 10: 6 → 5 (-1)

18% less capital invested

Capital invested by funds: $370M → $303M (-$67M)

20.46% less ownership

Funds ownership: 113.14% → 92.68% (-20%)

Holders
69
Holders Change
–
Holders Change %
0%
% of All Funds
1.21%
Holding in Top 10
5
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-16.67%
% of All Funds
0.09%
New
18
Increased
27
Reduced
11
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$12.3M
2
Millennium Management
Millennium Management
New York
+$6.93M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$5.34M
4
CC
Commodore Capital
New York
+$4.9M
5
GTC
Ghost Tree Capital
New York
+$4.81M

Top Sellers

1
Morgan Stanley
Morgan Stanley
New York
-$8.32M
2
O
OrbiMed
New York
-$7.36M
3
CCM
Consonance Capital Management
New York
-$6.85M
4
ACM
Altium Capital Management
New York
-$4.86M
5
LGM
Logos Global Management
California
-$4.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
DCM
26
Driehaus Capital Management
Illinois
$4.96M -$757K -78,584 -12%
TCM
27
Tekla Capital Management
Massachusetts
$4.72M – – –
NLVP
28
New Leaf Venture Partners
New York
$4.4M +$117K +12,150 +2%
APM
29
Avidity Partners Management
Texas
$3.67M -$981K -101,935 -20%
Citigroup
30
Citigroup
New York
$2.58M +$2.44M +253,048 +628%
Susquehanna International Group
31
Susquehanna International Group
Pennsylvania
$2.5M +$2.74M +284,250 New
JP Morgan Chase
32
JP Morgan Chase
New York
$2.18M +$1.74M +180,954 +269%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$2.17M +$334K +34,690 +16%
DCM
34
DAFNA Capital Management
California
$1.96M +$2.15M +223,554 New
ECM
35
ExodusPoint Capital Management
New York
$1.91M +$797K +82,780 +61%
SSA
36
Schonfeld Strategic Advisors
New York
$1.8M +$792K +82,234 +67%
MCM
37
Moore Capital Management
New York
$1.09M +$102K +10,616 +9%
SCM
38
Silverarc Capital Management
Massachusetts
$1.05M -$1.11M -115,066 -49%
AA
39
AlphaCentric Advisors
Puerto Rico
$790K +$677K +70,300 +357%
Morgan Stanley
40
Morgan Stanley
New York
$572K -$8.32M -864,304 -93%
Northern Trust
41
Northern Trust
Illinois
$529K +$64.9K +6,746 +13%
HF
42
HRT Financial
New York
$526K +$578K +60,012 New
Qube Research & Technologies (QRT)
43
Qube Research & Technologies (QRT)
United Kingdom
$431K +$472K +49,041 New
BCM
44
Bridgeway Capital Management
Texas
$422K +$12.4K +1,284 +3%
QSS
45
Quantitative Systematic Strategies
Florida
$419K +$104K +10,830 +29%
IC
46
Ikarian Capital
Texas
$367K – – –
Goldman Sachs
47
Goldman Sachs
New York
$341K +$275K +28,569 +277%
LP
48
LMR Partners
United Kingdom
$307K +$337K +35,009 New
VEA
49
Virtus ETF Advisers
New York
$247K +$271K +28,101 New
SAM
50
Sectoral Asset Management
Quebec, Canada
$237K +$260K +27,000 New
1
2
3 4

COGT Hedge Fund Activity: Q1 2021 in Review

69 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q1 2021, worth a combined $303M — down 18% from $370M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new COGT positions and 17 closed out — a net gain of 1 holder — while 27 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $12.3M. The largest seller was Morgan Stanley, cutting an estimated $8.32M.

  • 69 institutional investors held Cogent Biosciences (COGT) as of Q1 2021, unchanged from Q4 2020.
  • Funds reported $303M of Cogent Biosciences stock for Q1 2021, down 18% quarter-over-quarter.
  • 18 funds opened new Cogent Biosciences positions in Q1 2021 and 17 closed out, a net change of +1 holder.
  • The largest Cogent Biosciences buyer in Q1 2021 was Vanguard Group, an estimated $12.3M added.
  • The largest Cogent Biosciences seller in Q1 2021 was Morgan Stanley, an estimated $8.32M sold.

Based on aggregated 13F filings for Q1 2021.